← Leaderboards
Benjamin Izar
Dana-Farber Cancer Inst
$6,774,069
Attributed
$7,803,460
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,803,460 · 6
By mechanism
R01$3,253,964 · 2
R37$2,220,950 · 1
U54$1,089,772 · 1
K08$826,775 · 1
R21$411,999 · 1
Top collaborators
- Ashley Marie Laughney3 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Rameen Beroukhim$9,639,646
- Kai W Wucherpfennig$37,935,181
- Adam Joel Bass$9,339,125
- Andrew A Lane$4,246,865
- Piotr Sicinski$42,703,610
Others in their field
Other Emerging Leaders on “Molecular”
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,360,557
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$109,548,439
- Leonard Freedmand · Leidos Biomedical Research, Inc.$85,594,314
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Scott Hensley · University Of Pennsylvania$41,662,743
Research focus
MolecularCellsResponseImmune Checkpoint InhibitorSignal TransductionMalignant NeoplasmsResistanceMelanomaImmunotherapyCohortMultimodalityCancer CellImmuneMetastatic MelanomaT-LymphocyteTissuesTumorDrug ResistanceBiopsyMediatingMelanoma CellGeneticInnovationGenomics
Grant awards (24)
Multi-cellular interactions defining the human brain metastatic niche$692,427
R01 · FY2025 · CA · contact PI
Single-Cell, Spatial and Functional Dissection of Cancer Cell States, Co-Evolving Ecosystems, and Vulnerabilities During Tumor Progression and Metastasis$355,096
U54 · FY2025 · CA · contact PI
Mechanisms of liver metastasis and associated resistance to immunotherapy$338,826
R37 · FY2025 · CA · contact PI
Multi-cellular interactions defining the human brain metastatic niche$657,805
R01 · FY2024 · CA · contact PI
The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapy$388,273
R01 · FY2024 · CA · contact PI
Mechanisms of liver metastasis and associated resistance to immunotherapy$383,327
R37 · FY2024 · CA · contact PI
Single-Cell, Spatial and Functional Dissection of Cancer Cell States, Co-Evolving Ecosystems, and Vulnerabilities During Tumor Progression and Metastasis$349,808
U54 · FY2024 · CA · contact PI
Mechanisms of liver metastasis and associated resistance to immunotherapy$137,650
R37 · FY2024 · CA · contact PI
Multi-cellular interactions defining the human brain metastatic niche$708,550
R01 · FY2023 · CA · contact PI
The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapy$399,379
R01 · FY2023 · CA · contact PI
Mechanisms of liver metastasis and associated resistance to immunotherapy$397,013
R37 · FY2023 · CA · contact PI
Single-Cell, Spatial and Functional Dissection of Cancer Cell States, Co-Evolving Ecosystems, and Vulnerabilities During Tumor Progression and Metastasis$384,868
U54 · FY2023 · CA · contact PI
Mechanisms of liver metastasis and associated resistance to immunotherapy$144,895
R37 · FY2023 · CA · contact PI
Mechanisms of liver metastasis and associated resistance to immunotherapy$438,730
R37 · FY2022 · CA · contact PI
The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapy$407,530
R01 · FY2022 · CA · contact PI
Dissecting drug resistance in serial uveal melanoma biopsies using integrated, multi-modal single-cell profiling and novel machine learning tools.$222,661
R21 · FY2022 · CA · contact PI
Mechanisms of liver metastasis and associated resistance to immunotherapy$380,509
R37 · FY2021 · CA · contact PI
Dissecting drug resistance in serial uveal melanoma biopsies using integrated, multi-modal single-cell profiling and novel machine learning tools.$189,338
R21 · FY2021 · CA · contact PI
Dissecting mechanisms of immunotherapy resistance in melanoma patients$124,559
K08 · FY2021 · CA · contact PI
Dissecting mechanisms of immunotherapy resistance in melanoma patients$170,856
K08 · FY2020 · CA · contact PI
Dissecting mechanisms of immunotherapy resistance in melanoma patients$149,255
K08 · FY2019 · CA · contact PI
Dissecting mechanisms of immunotherapy resistance in melanoma patients$27,865
K08 · FY2019 · CA · contact PI
Dissecting mechanisms of immunotherapy resistance in melanoma patients$177,120
K08 · FY2018 · CA · contact PI
Dissecting mechanisms of immunotherapy resistance in melanoma patients$177,120
K08 · FY2017 · CA · contact PI